Research programme: opioid analgesics - AntaresAlternative Names: AP-159 - Antares
Latest Information Update: 06 Jul 2010
At a glance
- Originator Antares Pharma
- Class Pyridines
- Mechanism of Action Opioid receptor agonists; Opioid receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 12 Oct 2007 Antares Pharma signs development and licensing agreement with undisclosed pharmaceutical company for transmucosal opioid analgesic product
- 29 Nov 2006 Preclinical trials in Pain in USA (PO)